Federal workers get drug-cost transparency; PBMs lose hidden rebate profits

What it does

This bill requires pharmacy benefits managers (PBMs) administering drug benefits for federal employees to reimburse in-network pharmacies based on actual drug acquisition costs plus a small markup, pay state-level dispensing fees, pass manufacturer rebates to patients at point of sale, and prohibits PBMs from steering patients to affiliated pharmacies or restricting which pharmacies can fill prescriptions. The bill imposes civil penalties up to $10,000 per violation (capped at $100,000 per PBM per carrier per decade) and can debar PBMs after 10 violations, with enforcement by the Office of Personnel Management.

Why we flagged it

The bill's operative mechanism is a comprehensive reimbursement and conduct standard for pharmacy benefits managers in the federal employee health plan, designed to reduce hidden markups, eliminate steering incentives, and mandate rebate pass-through. It is regulatory reform, not a commemorative or appropriations measure.

What the text implies

• Mandatory rebate pass-through at point of sale may reduce PBM revenue from rebate arbitrage, potentially shifting PBM business models toward transparent service fees rather than hidden spread capture.
• Prohibition on affiliate steering and network restrictions may increase generic and independent pharmacy utilization, reducing captive-market dynamics that favor large retail chains.
• The 6-year statute of limitations for OPM enforcement actions creates a window for PBMs to cure violations before penalties accrue, potentially incentivizing compliance over litigation.
• Debarment after 10 violations in a 10-year period sets a high threshold; a PBM could incur $100,000 in penalties per carrier without losing the contract, limiting deterrent effect for large, diversified PBMs.
• The bill applies only to federal employee plans; state Medicaid and commercial plans remain unaffected, creating a two-tier market where federal employees receive stronger protections than the general public.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Federal employees and retirees gain lower out-of-pocket costs through mandatory rebate pass-through at point of sale, access to any in-network pharmacy without steering, and transparent reimbursement tied to actual acquisition costs. The restrictions on PBM self-dealing and affiliate steering directly reduce hidden markups and conflicts of interest that ordinarily inflate drug costs for consumers.

Who stands to gain

• independent pharmacies
• regional pharmacy chains
• federal employees and retirees (via lower copays and coinsurance)

Named in the bill

Office of Personnel Management (OPM), pharmacy benefits managers (PBMs), in-network pharmacies, federal employee health benefit plans, pharmaceutical manufacturers, state Medicaid programs, U.S. Department of Justice, U.S. District Courts

Where it stands

46 cosponsors: 27 Republicans, 19 Democrats.

• Dec 11, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 11, 2025 — Referred to House Committee on Oversight and Government Reform · Congress.gov: “Referred to the House Committee on Oversight and Government Reform”
• Jul 22, 2026 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Jul 22, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 2”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

11 lobbying clients named this bill on 15 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $19,632,656 in lobbying spend. A filing names 20 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 92% of bills with at least one filing.

Jake Auchincloss, the sponsor, reported $785,750 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• Pharmaceutical Care Management Association — $6,472,656 on 2 filings
• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• National Treasury Employees Union — $690,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.